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therefore hypothesise that decreased endogenous kiss-
peptin secretion is the common central pathway that links 
metabolic and endocrine factors in the pathology of testos-
terone deficiency seen in men with obesity and T2DM. We 
propose that the kisspeptin system plays a central role in in-
tegrating a range of metabolic inputs, thus constituting the 
link between energy status with the hypothalamic-pituitary-
gonadal axis, and put forward potential clinical studies to 
test the hypothesis.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Over the past few decades, obesity has become a glob-
al health challenge. Between 1980 and 2004 the preva-
lence of obesity increased from 15 to 33% in the United 
States – a pattern mirrored across the world  [1] . Inter-
linked with this, the number of people with type 2 diabe-
tes (T2DM) has also risen, and is predicted to rise further 
 [2] . There is also an emerging consensus that T2DM and 
obesity are part of the same disease spectrum such that 
the term ‘metabolic syndrome’ is used to describe these 
overlapping pathophysiological processes  [3] .
 Whilst the cardiovascular effects of T2DM and obe-
sity have been extensively studied, the impact on fertility 
and hypogonadism remains relatively under-explored. 
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 Abstract 
 Hypogonadism occurs commonly in men with type 2 diabe-
tes (T2DM) and severe obesity. Current evidence points to a 
decreased secretion of gonadotropin-releasing hormone 
(GnRH) from the hypothalamus and thereby decreased se-
cretion of gonadotropins from the pituitary gland as a cen-
tral feature of the pathophysiology in these men. Hypergly-
caemia, inflammation, leptin and oestrogen-related feed-
back have been proposed to make aetiological contributions 
to the hypogonadotropic hypogonadism of T2DM. However, 
the neuroendocrine signals that link these factors with mod-
ulation of GnRH neurons have yet to be identified. Kiss-
peptins play a central role in the modulation of GnRH secre-
tion and, thus, downstream regulation of gonadotropins and 
testosterone secretion in men. Inactivating mutations of the 
kisspeptin receptor have been shown to cause hypogonado-
tropic hypogonadism in man, whilst an activating mutation 
is associated with precocious puberty. Data from studies in 
experimental animals link kisspeptin expression with indi-
vidual factors known to regulate GnRH secretion, including 
hyperglycaemia, inflammation, leptin and oestrogen. We 
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Low testosterone concentrations in men have been shown 
to be associated with obesity and T2DM  [4] . Plasma-free 
testosterone, total testosterone and sex hormone-binding 
globulin are low in obesity and recover in proportion to 
the degree of weight loss  [5] . In men with established 
T2DM, decreased plasma-free testosterone is found in a 
third to half of all patients  [6] .
 The relationship between hypogonadism and meta-
bolic status, consistently seen across race and ethnic 
groups  [7] , also seems to be bidirectional. In obese men, 
biochemical hypogonadism (low testosterone) increases 
the risk of future development of diabetes  [8] . In hypogo-
nadal individuals with T2DM, treatment with testoster-
one improves the glucose and lipid profile  [9] , and en-
hances quality of life and cardiac performance  [10] .
 The pathophysiology of low plasma testosterone in 
men with T2DM as well as the broader neuroendocrine 
signalling processes by which the metabolic milieu in-
fluences reproduction remains poorly understood  [11] . 
However, the recent discovery of kisspeptin and its cog-
nate receptor GPR-54  (KISS1R) as modulators of GnRH 
and, thus, downstream secretion of gonadotropins and 
testosterone  [12] may help solve at least a part of this com-
plex jigsaw.
 Here we review human and animal experimental data 
on the potential role for kisspeptin in mediating meta-
bolic inputs that modulate the hypothalamic-pituitary-
gonadal (HPG) axis and put forward propositions for 
clinical studies to test this central role for kisspeptin as 
an integrator of metabolic cues with reproductive func-
tion in men with metabolic syndrome.
 Hypothesis 
 We hypothesise that decreased endogenous kisspeptin 
secretion plays a central role in mediating hypogonado-
tropic hypogonadism in men with obesity and T2DM.
 Hypogonadism in Obesity and Diabetes 
 A number of possible pathologies have been proposed 
as causative factors for hypogonadism in individuals with 
obesity and/or T2DM. Metabolic factors (hyperglycae-
mia, inflammation, oxidative stress) and testicular fac-
tors (decreased Leydig cell function) have all been pro-
posed as factors contributing to the hypogonadal state in 
these individuals  [4] . However, current evidence points to 
a decreased secretion of gonadotropin-releasing hor-
mone (GnRH) from the hypothalamus as the key factor 
 [4] , as evidenced by the low or relatively low luteinising 
hormone (LH) and follicle-stimulating hormone (FSH) 
concentrations in the large majority of these men with 
low plasma testosterone. LH pulse amplitude and secre-
tory masses are significantly lower in obese men than in 
lean controls  [13] . Moreover, there is a highly significant 
negative correlation between plasma-free testosterone 
and body mass  [13] . A normal LH and FSH response to 
GnRH has also been demonstrated in obese individuals, 
suggesting a hypothalamic rather than a pituitary defect. 
 [14] .
 The Role of Kisspeptin in GnRH Secretion 
 Kisspeptins are peptide products of the  KISS1 gene 
 [15] . Various forms of kisspeptin have been identified, all 
of which have the same decapeptide amino acid sequence 
at the C-terminus  [12] . Kisspeptins regulate the repro-
ductive axis by stimulation of their cognate receptor 
 KISS1R (also called GPR-54) on GnRH neurons, thereby 
regulating LH and FSH secretion  [12] . Administration of 
kisspeptin has been shown to increase plasma LH, FSH 
and testosterone in a dose-dependent manner in a num-
ber of species including man  [16] , and a central role of 
kisspeptin in the metabolic regulation of reproductive 
function is well-recognised  [17] . Patients with mutations 
of  KISS1R exhibit hypogonadotropic hypogonadism but 
normal responses to GnRH and no reported metabolic 
derangement  [18–20] . It is also important to note that 
metabolic abnormalities have not been reported in knock-
out models lacking kisspeptin or its receptor  [21] , sug-
gesting that perturbation in the kisspeptin system is more 
likely to be the effect rather than the cause of a metabolic 
phenotype.
 In rodents, two distinct populations of kisspeptin neu-
rons exist in the arcuate (ARC) and anterior periventric-
ular (AVPV) nuclei, with differential functional respons-
es  [22] . Kisspeptin neurons in the ARC have been shown 
to respond to negative feedback by gonadal steroids, while 
AVPV kisspeptin neurons in the female rodent respond 
to positive feedback by oestrogen  [22] . However, AVPV is 
not an anatomical area present in the human hypothala-
mus and no kisspeptin neurons have been demonstrated 
in the corresponding rostral periventricular region of the 
third ventricle in humans  [22] . The infundibular nucleus 
is the human homologue of the ARC where the presence 
of kisspeptin neurons has been documented  [23] . In the 
rodent data reviewed here, we will focus on the kisspeptin 
population in the ARC nucleus as the oestrogen-mediat-
ed positive feedback seen in the female is not of particular 
relevance in the context of male hypogonadism. Howev-
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gene expression, whole hypothalami are often used rath-
er than specific nuclei, such as the ARC or AVPV, thus 
potentially lowering the sensitivity and specificity of any 
changes detected in Kiss1 mRNA expression.
 Support for the Hypothesis 
 Oestrogen-Mediated Negative Feedback and 
Kisspeptin 
 Peripheral conversion of androgens to oestrogens in 
obese men leads to increased circulating oestrogens, 
which in turn suppress the hypothalamic-pituitary axis 
and thus the production of testosterone  [24] . Serum oes-
trone and 17-  -estradiol are elevated twofold in morbid-
ly obese men, with the urinary excretion rates of these 
hormones elevated in proportion to the degree of obesity 
 [24] . Treatment with an aromatase inhibitor (preventing 
conversion of testosterone to estradiol) produces a sus-
tained normalisation of serum total testosterone in obese 
men with hypogonadism  [25] .
 However, adult GnRH neurons lack oestrogen recep-
tor-  (ER-  ) and rely on signaling from other oestrogen 
responsive hypothalamic neurons to facilitate oestrogen-
mediated regulation  [26] . The phenotypic identity of cells 
that receive input from gonadal steroids and relay this 
information to GnRH neurons remains unknown; how-
ever, kisspeptin neurons appear likely to play this role 
 [27] . The hypothalamic content of  Kiss1  (mRNA) increas-
es significantly after gonadectomy and decreases with sex 
steroid replacement  [28] . Kisspeptin neurons in sheep ex-
press ER-  receptors  [29] and in mouse models that lack 
functional ER-  receptors,  Kiss1  mRNA expression does 
not change in response to estradiol treatment  [30] . A mi-
nority of kisspeptin neurons express the oestrogen recep-
tor isoform ER-  in addition to ER-   [30] . In the absence 
of ER-  (in knockout mouse models), the inhibitory ef-
fect of E2 on transcription of  Kiss1 is enhanced  [30] , in-
dicating functional roles of both ER types in the regula-
tion of kisspeptin neurons.
 Leptin and Kisspeptin 
 Leptin secreted from adipocytes conveys information 
about the body’s energy stores to the brain and thus regu-
lates a number of physiological processes, including in-
flammation, immune function and reproduction  [31] . 
Humans and mice lacking leptin (ob/ob mice) or leptin 
receptor (db/db mice) develop obesity, insulin-resistant 
diabetes and hypogonadism  [31] . In obese men, circulat-
ing androgen is inversely correlated with circulating 
leptin  [32] and a functional resistance to leptin in human 
obesity has been described  [33] .
 GnRH neurons, however, show little or no expression 
of Ob-R mRNA  [34] and, therefore, must rely on interme-
diary neurons for transmission of information on leptin 
concentrations  [34] . Kisspeptin neurons may fulfill this 
role, as they express leptin receptors  [35] . Reversal of fast-
ing-induced inhibition of gonadotropins by exogenous 
kisspeptin  [36] and the ability of intracerebroventricular 
kisspeptin administration to correct the decrease in LH 
secretion seen in pubertal animals after central immu-
noneutralisation of endogenous leptin with antileptin an-
tibody  [37] provide further evidence for a role of kiss-
peptin in affecting the influence of leptin on the HPG axis.
 Hypothalamic  Kiss1  mRNA expression is significant-
ly reduced in ob/ob compared to wild-type mice and are 
increased in ob/ob mice treated with leptin  [35, 38] . More-
over, administration of leptin increases hypothalamic 
 Kiss1  mRNA as well as LH and testosterone concentra-
tions in hypogonadotropic diabetic male rats  [38] .
 Hyperglycaemia and Kisspeptin 
 Plasma testosterone is inversely related to glycaemic 
control in men with T2DM. However, when compared 
with age- and BMI-matched men  [4] as well as men with 
type 1 diabetes of a comparable age, men with T2DM 
have a higher prevalence of hypogonadism  [39] . This sug-
gests insulin resistance as well as hyperglycaemia could 
also play a role in the pathogenesis of hypogonadism in 
this setting  [4] . Mice with neuron-specific deletion of in-
sulin receptors (NIRKO mice) have increased body mass 
and hypogonadotropic hypogonadism, confirming that 
insulin sensing in the brain is required for normal activ-
ity of the HPG axis  [40] .
 Hypothalamic  Kiss1  mRNA  is decreased in strepto-
zotocin-induced diabetic rats (a model of type 1 diabetes), 
and the post-orchidectomy rise in  Kiss1  mRNA  in these 
hyperglycaemic animals is severely blunted  [38] . Kiss-
peptin administration has been shown to evoke robust 
LH and testosterone secretion and enhance post-gonad-
ectomy LH concentrations in hypogonadotropic strepto-
zotocin-induced diabetic male rats  [38] . Repeated admin-
istration of kisspeptin to diabetic rats also partially res-
cued prostate and testis weights  [41] . However, no studies 
have yet been carried out on  Kiss1  mRNA expression in 
animal models of T2DM.
 Inflammation and Kisspeptin 
 Obesity and T2DM are now well recognised to be as-



























 Kisspeptin Mediates Male 
Hypogonadism  
Neuroendocrinology 2010;91:302–307 305
stress  [42] . Circulating C-reactive protein, an inflamma-
tory marker associated with cardiovascular risk, has been 
shown to be significantly higher in hypogonadal men 
with T2DM in comparison to men with normal plasma 
testosterone  [4] .
 There are emerging data linking kisspeptin and in-
flammation. Administration of a pro-inflammatory 
agent (lipopolysaccharide) decreased hypothalamic  Kiss1 
 mRNA  expression as well as plasma LH in ovariec-
tomised rats  [43] . Indomethacin, an anti-inflammatory 
drug, completely blocked both these suppressive effects 
 [43] . Whilst inflammation has long been recognised to 
suppress the reproductive axis (e.g. in severe or chronic 
illness), these early findings suggest a link between kiss-
peptin and inflammation.
 Figure 1 summarises the normal physiology and the 
proposed pathophysiology underpinning our hypothesis.
 Testing the Hypothesis 
 To test the hypothesis directly, comparison between 
endogenous kisspeptin secretion in obese and lean sub-
jects would have to be made. However, the concentration 
of kisspeptin entering the peripheral circulation from the 
hypothalamus is likely to be undetectable. Accessing por-
tal circulation via petrosal sinus sampling for sampling is 
technically and ethically challenging. Highly specific and 
sensitive assay methods to measure kisspeptins are not 
yet widely available  [44, 45] . Moreover, even if the techni-
cal barriers are overcome, circulatory concentrations of 
kisspeptin may not correlate with the intracranial milieu.
 Recent advances in kisspeptin biology offer indirect al-
ternatives to test our hypothesis. Kisspeptin neuronal hy-
pertrophy and increased kisspeptin gene expression has 
been demonstrated in the hypothalamic infundibular nu-
 Fig. 1. Normal physiology and the patho-
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cleus in postmenopausal women  [23] . Similar post-mor-
tem histological analysis of hypothalami from obese men 
may show hypotrophy of kisspeptin neurons and/or de-
creased  KISS1 expression. A comparable situation of hy-
pogonadotropic hypogonadism is seen in women with hy-
pothalamic amenorrhoea who show a significantly higher 
LH response to acute administration of kisspeptin-54 in 
comparison to healthy women in the follicular phase of 
menstrual cycle  [46] . As hypogonadal men with metabol-
ic syndrome have a similar gonadotropin profile to wom-
en with hypothalamic amenorrhoea, stimulatory re-
sponses in LH to exogenous kisspeptin in these men may 
also be increased, which if confirmed in exploratory stud-
ies, raises the possibility of using a provocative kisspeptin 
stimulation test as a marker of metabolic status. In recent 
animal studies, kisspeptin antagonists have been shown 
to inhibit kisspeptin-induced LH release and also block 
the post-gonadectomy rise in LH  [47] . Moreover, in male 
rats with streptozocin-induced diabetes, the LH response 
to kisspeptin was significantly higher than control ani-
mals  [48] . By analogy, increased sensitivity to kisspeptin 
analogues in men with hypogonadism associated with 
T2DM would indirectly lend support to our hypothesis. 
Such studies could be performed by acute stimulation 
with a single dose of kisspeptin, akin to the GnRH pro-
vocative test used in numerous clinical settings.
 Implications of the Hypothesis 
 There are physiological and clinical implications if our 
postulates are correct.
 The pathophysiology of hypogonadism in obese men 
remains poorly understood. Current evidence linking in-
sulin, leptin, oestrogen and inflammation with hypogo-
nadism fails to explain how these factors have effects on 
GnRH neurons which lack corresponding receptors. If 
our hypothesis is correct, kisspeptin will constitute the 
neuroendocrine link conveying information about whole 
body energy balance to the GnRH neuronal system.
 From a translational perspective, there is potential for 
pharmacological therapies to be developed to address hy-
pogonadism. A number of kisspeptin analogues are be-
ing developed with agonistic and antagonistic activities. 
If our hypothesis is correct, kisspeptin agonists consti-
tute putative therapeutic targets for low circulating tes-
tosterone seen in obesity and diabetes. Current treatment 
of hypogonadism with testosterone tends to decrease 
sperm production through negative feedback on FSH se-
cretion with resultant sub-fertility in at least some pa-
tients. Pharmacological modulation with kisspeptin ago-
nists will potentially not have this adverse effect.
 In  summary,  we   postulate   low   kisspeptin   secretion 
is part of the pathophysiology of hypogonadotropic hy-
pogonadism seen in men with obesity and T2DM. The 
kisspeptin/KISS1R system is likely to be a central link be-
tween energy status and the HPG axis in man as has been 
demonstrated in experimental animals.
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